Toralizumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized |
| Target | ligand CD40 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| Chemical and physical data | |
| Molar mass | Approximately 148,426 Daltons |
Toralizumab is a humanized monoclonal antibody used as an immunosuppressive drug. It is used in multiple treatments of antibody-mediated disorders (immune thrombocytopenic purpura, lupus nephritis, rheumatoid arthritis), T-cell-mediated diseases (multiple sclerosis, Crohn's disease, and transplantations such as solid organ transplantation, pancreatic islet cell transplantation, and corneal transplantation), and B-cell malignancies such as CLL/small lymphocytic lymphoma, follicular cell lymphoma grade I or II, marginal zone lymphoma, mantle cell lymphoma, MALT lymphoma, Waldenstrom's macroglobulinemia, monocytoid B-cell lymphoma; relapsed/refractory Hodgkin's disease).[1]
The drug was developed by IDEC Pharmaceuticals Corporation.
References
- ^ STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL - TORALIZUMAB, American Medical Association.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |